Megan Teynor

Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden

Santiago Zuluaga-Sanchez, Megan Teynor, C Knight et al. · PharmacoEconomics · 2019 · 66 citations · Full text

Pharmacy, Pediatrics, Pharmacoeconomics +16

<p>Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular Atrophy</p>

Andrew Lloyd, Robin Thompson, Katy Gallop et al. · ClinicoEconomics and Outcomes Research · 2019 · 31 citations · Full text

Pharmacy, Pharmacoeconomics, Cost-effectiveness Analysis +16

Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic

Robert Desborough, Philip Nicklin, Fatma Gossiel et al. · Bone · 2020 · 30 citations · Full text

Medicine, Endocrinology, Bone Metabolism +16

The Utility of Different Approachs to Developing Health Utilities Data in Childhood Rare Diseases – A Case Study in Spinal Muscular Atrophy (SMA)

Robin Thompson, Shalvaree Vaidya, Megan Teynor · Value in Health · 2017 · 20 citations

Public Health, Child Health, Health Sciences +9

Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study

Aaron Yarlas, Geert D’Haens, Mary Kaye Willian et al. · Inflammatory Bowel Diseases · 2018 · 13 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17